| Literature DB >> 26991559 |
Valentina Tomassini1,2,3, Alessandro d'Ambrosio1,2,4, Nikolaos Petsas5, Richard G Wise2, Emilia Sbardella5, Marek Allen2, Francesca Tona5, Fulvia Fanelli5, Catherine Foster2, Marco Carnì5, Antonio Gallo4, Patrizia Pantano5,6, Carlo Pozzilli5.
Abstract
Brain plasticity is the basis for systems-level functional reorganization that promotes recovery in multiple sclerosis (MS). As inflammation interferes with plasticity, its pharmacological modulation may restore plasticity by promoting desired patterns of functional reorganization. Here, we tested the hypothesis that brain plasticity probed by a visuomotor adaptation task is impaired with MS inflammation and that pharmacological reduction of inflammation facilitates its restoration. MS patients were assessed twice before (sessions 1 and 2) and once after (session 3) the beginning of Interferon beta (IFN beta), using behavioural and structural MRI measures. During each session, 2 functional MRI runs of a visuomotor task, separated by 25-minutes of task practice, were performed. Within-session between-run change in task-related functional signal was our imaging marker of plasticity. During session 1, patients were compared with healthy controls. Comparison of patients' sessions 2 and 3 tested the effect of reduced inflammation on our imaging marker of plasticity. The proportion of patients with gadolinium-enhancing lesions reduced significantly during IFN beta. In session 1, patients demonstrated a greater between-run difference in functional MRI activity of secondary visual areas and cerebellum than controls. This abnormally large practice-induced signal change in visual areas, and in functionally connected posterior parietal and motor cortices, was reduced in patients in session 3 compared with 2. Our results suggest that MS inflammation alters short-term plasticity underlying motor practice. Reduction of inflammation with IFN beta is associated with a restoration of this plasticity, suggesting that modulation of inflammation may enhance recovery-oriented strategies that rely on patients' brain plasticity. Hum Brain Mapp 37:2431-2445, 2016.Entities:
Keywords: brain plasticity; functional MRI; inflammation; interferon beta; multiple sclerosis
Mesh:
Substances:
Year: 2016 PMID: 26991559 PMCID: PMC5069650 DOI: 10.1002/hbm.23184
Source DB: PubMed Journal: Hum Brain Mapp ISSN: 1065-9471 Impact factor: 5.038
Figure 1Study design and measurements. Patients were assessed using behavioural and MRI measures twice before (at session 1, week −6 ± 1, and at session 2, baseline) and once after (at session 3, week +12 ± 1) the beginning of IFN beta. Age‐ and sex‐matched healthy volunteers were assessed behaviourally and with MRI at session 1 only. During each session, participants were assessed using behavioural measures. Patients were also assessed using the EDSS score. Patients underwent conventional MRI acquisitions to detect the presence and quantify the number of Gd‐enhancing and T2‐hyperintense lesions, and to quantify GM volume. Motor task fMRI consisting of the repetition of directionally specific, voluntary, visually cued TF movements before (run 1) and after (run 2) 25 minutes of TF training was acquired in MS patients in the three scanning sessions and in healthy volunteers in session 1. The fMRI data analysis tested (a) within‐ and between‐group changes in brain activation associated with training at session 1; (b) changes in training‐related functional responses with IFN beta in the patients. Abbreviations: EDSS= Expanded Disability Status Scale; fMRI= functional MRI; Gd= Gadolinium; IFN= Interferon; GM= Grey Matter; 9‐HPT= Nine Hole Peg Test; PASAT= Paced Auditory Serial Addition Test; S= Session; T25‐FW= Timed 25‐Foot Walk; TF= Thumb Flexion; WI= Weighted Image.
Cohorts' characteristics
| Patients (n=26) | Controls (n=22) |
| |
|---|---|---|---|
| Age | 36.1 ± 1.4 | 33.5 ± 1.7 | 0.23 |
| Sex (F/M) | 21/5 | 16/6 | 0.51° |
| Disease duration (months) | 21.7 ± 6.1 | – | – |
| EDSS score (median, range) | 1.5, 0–3.0 | – | – |
| Mean 9‐HPT (Right) | 17.8 ± 0.4 | 15.8 ± 0.4 | 0.002 |
| Mean 9‐HPT (Left) | 19.3 ± 0.7 | 17.1 ± 0.4 | 0.01 |
| Mean T25‐FW | 5.8 ± 0.3 | 5.3 ± 0.1 | 0.09 |
| No. correct responses PASAT 3s | 43.1 ± 1.9 | 49.1 ± 2.3 | 0.05 |
| No. correct responses PASAT 2s | 33.8 ± 2.1 | 40.7 ± 2.4 | 0.04 |
| No. Gd+ MRI scans | 14/26 | – | – |
| T2 hyperintense lesion volume (mm3) | 2863.6 ± 531.1 | – | – |
Chi‐square test.
Values are reported as mean ± SE, unless indicated otherwise. The 9‐HPT and T25‐FW are expressed as the mean of two trials. Significance is tested using two‐tailed unpaired t test, unless stated otherwise. Abbreviations: EDSS = Expanded Disability Status Scale; Gd+ MRI scans= scan with at least one gadolinium‐enhancing lesion; 9‐HPT= 9‐hole peg test; PASAT= Paced Auditory Serial Addition Test; SE = standard error; T25‐FW= timed 25‐foot walk.
Main effect of the thumb flexion task (run 1, session 1) in patients and in controls
| Patients (n=26) | Controls (n=22) | |||||||
|---|---|---|---|---|---|---|---|---|
| MNI Coordinates | MNI Coordinates | |||||||
| L PMd | 10.5 | −24 | −14 | 66 | 10.2 | −58 | −2 | 34 |
| R PMd | 6.5 | 58 | 2 | 34 | 5.1 | 56 | 4 | 34 |
| L SMC | 10.8 | −34 | −14 | 62 | 10.3 | −4 | −2 | 54 |
| R SMC | 6.5 | 6 | 4 | 54 | 5.1 | 6 | 0 | 54 |
| L M1 | 11.0 | −34 | −20 | 52 | 10.6 | −34 | −20 | 52 |
| R M1 | 6.5 | 42 | −12 | 52 | 3.2 | 42 | −10 | 52 |
| L S1 | 10.8 | −30 | −34 | 48 | – | – | – | – |
| L IPL | 11.2 | −52 | −32 | 40 | 11.3 | −58 | −36 | 24 |
| R IPL | 6.7 | 58 | −22 | 40 | 4.3 | 64 | −26 | 24 |
| L SPL | 6.3 | −36 | −44 | 48 | 5.3 | −34 | −48 | 48 |
| R SPL | 5.5 | 38 | −44 | 48 | 4.9 | 38 | −52 | 48 |
| L V3 | 6.1 | −28 | −92 | −2 | 3.02 | −32 | −94 | −10 |
| R V3 | 5.5 | 30 | −88 | −2 | – | – | – | – |
| L V5 | 6.8 | −50 | −66 | −2 | 6.1 | −50 | −64 | −2 |
| R V5 | 6.0 | 56 | −60 | −2 | 5.6 | 52 | −58 | −2 |
| L Putamen | 7.7 | −24 | −4 | 2 | 7.14 | −26 | 0 | 2 |
| R Putamen | 6.1 | 24 | 4 | −2 | 5.6 | 24 | 4 | −2 |
| L Pallidum | 9.1 | −22 | −8 | 2 | 7.4 | −20 | −4 | 2 |
| R Pallidum | 6.4 | 22 | −6 | 2 | 5.6 | 22 | −6 | 2 |
| L Thalamus (Premotor) | 7.2 | −10 | −22 | 2 | 7.64 | −12 | −20 | 0 |
| R Thalamus (Prefrontal) | 7.0 | 10 | −20 | 0 | 5.7 | 10 | −22 | 0 |
| R Cerebellum (lobule VI) | 7.8 | 6 | −62 | −18 | 9.97 | 22 | −66 | −26 |
| R Cerebellum (lobule VIIIa) | 8.0 | 16 | −66 | −54 | 6.71 | 18 | −64 | −54 |
Localization of clusters is in Montreal Neurological Institute (MNI) Standard Brain Space. Z score of the peak voxel is reported for each cluster showing the main effect of the thumb flexion task in patients and in controls (random effects, Z > 2.3, P < 0.05, corrected). Thalamic and cerebellar regions connected to specific cortical regions are reported in brackets.
Abbreviations: PMd = dorsal premotor cortex; SMC = supplementary motor cortex; M1 = primary motor cortex; S1 = primary somatosensory cortex; IPL = intraparietal lobule; SPL = superior parietal lobule; V = visual cortex; R = right; L = left.
Figure 2Training‐dependent fMRI signal changes in healthy volunteers and in MS patients during session 1. Maps of training‐related fMRI signal changes (contrasting run 1 vs. run 2) during session 1 are reported in healthy volunteers (indicated as controls) and in patients (Z > 2.3, P < 0.05, cluster corrected). Comparison between patients and controls showed a higher signal reduction in the patients in regions corresponding to the secondary visual areas (V2 and V4) and in the cerebellum (lobule V‐VI). Abbreviations: V= visual cortex; R= right hemisphere.
Training‐related functional changes
|
| ||||||||
|---|---|---|---|---|---|---|---|---|
| Patients (n=26) | Controls (n=22) | |||||||
| MNI Coordinates | MNI Coordinates | |||||||
| L FP | 4.4 | −40 | 42 | 18 | – | – | – | – |
| R FP | 4.0 | 42 | 46 | 18 | 3.1 | 36 | 54 | 8 |
| L IC | 2.9 | −38 | 2 | 4 | 3.2 | −38 | 14 | −4 |
| R IC | 3.9 | 36 | 2 | 4 | 3.1 | 32 | 14 | 8 |
| L Cingulate | 5.8 | −6 | 10 | 34 | 3.5 | −2 | 14 | 28 |
| R Cingulate | 5.2 | 6 | 14 | 34 | 3.0 | 8 | 10 | 36 |
| L BA | 4.7 | −56 | 4 | 18 | 3.0 | −54 | 2 | 18 |
| R BA | 4.0 | 56 | 10 | 26 | 3.6 | 52 | 4 | 26 |
| L PMd | 5.3 | −26 | −8 | 46 | 4.3 | −52 | 2 | 36 |
| R PMd | 3.8 | 50 | −2 | 46 | 3.7 | 44 | 2 | 46 |
| L IPL | 5.6 | −56 | −26 | 34 | 4.4 | −58 | −28 | 34 |
| R IPL | 5.2 | 60 | −24 | 34 | 4.1 | 62 | −22 | 34 |
| L ITG | 4.3 | −48 | −62 | −14 | 4.2 | −48 | −58 | −8 |
| R ITG | 5.6 | 54 | −60 | −14 | 4.9 | 56 | −56 | −8 |
| L S1 | 5.2 | −58 | −22 | 36 | 4.0 | −44 | −24 | 36 |
| R S1 | 3.8 | 58 | −14 | 36 | 4.7 | 54 | −20 | 36 |
| L V5 | 5.5 | −54 | −70 | 4 | 4.2 | −48 | −72 | −8 |
| R V5 | 4.9 | 50 | −60 | 4 | 2.9 | 54 | −64 | −8 |
| L Caudate | 2.9 | −18 | 16 | 8 | – | – | – | – |
| R Caudate | 4.5 | 16 | 14 | 8 | – | – | – | – |
| L Putamen | 4.2 | −26 | −2 | 4 | 3.0 | −20 | 10 | 0 |
| R Putamen | 2.9 | 30 | 4 | 6 | 2.7 | 22 | 14 | −4 |
| L Pallidum | 3.7 | −16 | −2 | 0 | 2.9 | −16 | 6 | 0 |
| R Pallidum | 3.0 | 20 | 0 | 0 | 2.9 | 20 | 4 | 0 |
| L Thalamus (Prefrontal) | 3.8 | −14 | −22 | 12 | 4.0 | −12 | −16 | 0 |
| R Thalamus (Prefrontal) | 4.8 | 10 | −14 | 8 | – | – | – | – |
| L Cerebellum (lobule VI) | 5.4 | −24 | −56 | −26 | 4.5 | −28 | −66 | −24 |
| R Cerebellum (lobule VI) | 5.3 | 26 | −52 | −28 | 4.8 | 26 | −52 | −30 |
| L Cerebellum (crus I) | 5.4 | −32 | −68 | −26 | 3.5 | −38 | −52 | −36 |
| R Cerebellum (crus I) | 5.0 | 26 | −72 | −26 | 3.1 | 34 | −56 | −34 |
| L Cerebellum (lobule VIIIa) | 4.4 | −16 | −66 | −50 | 5.0 | −28 | −58 | −56 |
|
| ||||||||
| Session 2 (n=24) | Session 3 (n=24) | |||||||
| MNI Coordinates | MNI Coordinates | |||||||
| L FP | 3.1 | −40 | 38 | 22 | 3.8 | −42 | 40 | 16 |
| R FP | 3.2 | 32 | 48 | 24 | – | – | – | – |
| L IC | 3.5 | −32 | 16 | 4 | 4.4 | −32 | 16 | 2 |
| R IC | 3.0 | 32 | 16 | 4 | 3.8 | 38 | 4 | 2 |
| L Cingulate | 2.9 | −6 | 6 | 40 | 4.4 | −8 | 16 | 28 |
| R Cingulate | 3.6 | 4 | 18 | 28 | 4.4 | 10 | 10 | 32 |
| L PMv | 3.7 | −56 | 2 | 22 | 4.5 | −58 | 4 | 24 |
| R PMv | – | – | – | – | 3.2 | 60 | 4 | 24 |
| L S1 | 3.6 | −42 | −42 | 50 | 3.3 | −40 | −42 | 50 |
| R S1 | 3.7 | 46 | −34 | 52 | 2.8 | 38 | −40 | 50 |
| L IPL | 5.6 | −58 | −32 | 34 | 5.5 | −62 | −28 | 34 |
| R IPL | 4.6 | 62 | −28 | 34 | 5.0 | 64 | −28 | 36 |
| L V1 | 3.3 | −10 | −80 | 8 | – | – | – | – |
| R V1 | 3.6 | 20 | −74 | 8 | – | – | – | – |
| L V2 | 3.3 | −6 | −86 | −2 | – | – | – | – |
| L V5 | 3.3 | −50 | −66 | −2 | 2.9 | −54 | −64 | −2 |
| R V5 | 3.3 | 46 | −64 | 8 | – | – | – | – |
| R Caudate | 3.6 | 16 | 14 | 6 | – | – | – | – |
| L Putamen | – | – | – | – | 3.8 | −22 | 10 | 0 |
| R Putamen | 3.1 | 26 | 4 | 10 | 3.5 | 24 | 10 | 0 |
| L Thalamus (prefrontal) | 3.9 | −10 | −18 | 6 | 3.5 | −8 | −14 | 0 |
| R Thalamus (prefrontal) | 5.3 | 16 | −12 | 6 | 4.6 | 10 | −16 | 0 |
| L Cerebellum (lobule VI) | 3.5 | −32 | −52 | −34 | 4.2 | −30 | −58 | −32 |
| R Cerebellum (lobule VI) | 3.9 | 30 | −52 | −32 | 4.0 | 26 | −64 | −32 |
| L Cerebellum (crus I) | 4.9 | −40 | −52 | −34 | 3.8 | −40 | −48 | −34 |
| R Cerebellum (crus I) | 3.7 | 48 | −54 | −34 | 4.0 | 36 | −52 | −36 |
| R Cerebellum (lobule VIIIa) | 3.3 | 16 | −64 | −56 | 4.0 | 10 | −64 | −52 |
Localization of clusters is in Montreal Neurological Institute (MNI) Standard Brain Space. Z score of the peak voxel is reported for each cluster showing the effect of thumb flexion training in patients and in controls during session 1 and in patients only during session 2 vs. 3 (random effects, Z > 2.3, P < 0.05, corrected). Thalamic and cerebellar regions connected to specific cortical areas are reported in brackets.
Abbreviations: BA = Broca's area; FP = frontal pole; IC = insular cortex; IPL = inferior parietal lobule; ITG = inferior temporal gyrus; PMd = dorsal premotor cortex; PMv = ventral premotor cortex; M1 = primary motor cortex; S1 = primary somatosensory cortex; V = visual cortex; R = right; L = left.
Figure 3Training‐dependent fMRI signal changes in MS patients during session 2 vs. session 3. Maps of training‐related fMRI signal changes (contrasting run 1 vs. run 2) are reported in session 2 (before IFN beta) vs. session 3 (on IFN beta) in patients with MS (Z > 2.3, P < 0.05, cluster corrected). Comparing session 2 with session 3, patients showed a reduction of the training‐dependent fMRI signal changes after 12 weeks of IFN beta treatment in a cluster of regions encompassing the sensorimotor (M1, S1), temporal (MTG), visual (V2) and parietal (AIPS, IPL, SPL) cortices. Abbreviations. AIPS= anterior intraparietal sulcus; IPL= inferior parietal lobule; M1= primary motor cortex; MTG= middle temporal gyrus; S1= primary somatosensory cortex: SPL= superior parietal lobule.
Figure 4Variation in training‐induced fMRI signal changes over time in functionally defined regions of interest (ROIs). In the patients, differences across sessions in training‐related fMRI signal reductions (contrasting run 1 vs. run 2, with greater reductions shown as more positive values) are shown in ROIs derived from the map of the session 2 vs. session 3 contrast. In the healthy volunteers (indicated as controls) training‐related signal reductions are reported for session 1 only. In the patients, the training‐related reduction in functional signal was less in session 3 (on IFN beta) than in session 2 (before IFN beta) and largely stable from session 1 to session 2 (before IFN beta), suggesting a drug effect on brain plasticity. Abbreviations: ROI= region of interest; S= session.